-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1882 Host Tissue PD-L1 Separates GVL Effect from Gvhd after Temporary Depletion of Donor CD4+ T Cells Early after HCT

Experimental Transplantation: Immune Function, GVHD and Graft-versus-Tumor Effects
Program: Oral and Poster Abstracts
Session: 702. Experimental Transplantation: Immune Function, GVHD and Graft-versus-Tumor Effects: Poster I
Saturday, December 5, 2015, 5:30 PM-7:30 PM
Hall A, Level 2 (Orange County Convention Center)

Xiong Ni, MD1,2*, Qingxiao Song, MD1,3*, Ruishu Deng, MD, PhD4*, Hua Jin, BS5,6*, Kaniel M. Cassady, BS7,8*, Mingfeng Zhang, PhD6*, Stephen J. Forman, MD9,10,11, Paul J. Martin, MD12, Jianmin Wang, MD. Ph.D13 and Defu Zeng, MD8,14,15

1The Beckman Research Institute of City of Hope, Departments of Diabetes Research and Hematology/Hematopoietic Cell Transplantation, Duarte, CA
2The Second Military Medical University, Department of Hematology, Changhai Hospital, Shanghai, China
3Fujian Institute of Hematology, Fujian Medical University Union Hospital, Department of Hematology, Fuzhou, China
4Beckman Research Institute, City of Hope National Medical Center, Duarte
5Nanfang Hospital, Southern Medical University, Department of Hematology, Guangzhou, China
6The Beckman Research Institute of City of Hope, Departments of Diabetes Research and Hematology/Hematopoietic Cell Transplantation, Duarte
7Department of Diabetes and Hematology/Hematopoietic Cell Transplantation, The Beckman Research Institute of City of Hope, Duarte, CA
8Irell and Manella Graduate School of Biological Sciences, Duarte, CA
9City of Hope National Medical Center, Duarte, CA
10Irell and Manella Graduate School of Biological Sciences of City of Hope, Duarte, CA
11Gehr Leukemia Center, City of Hope Medical Center, Duarte, CA
12Fred Hutchinson Cancer Research Center, Seattle, WA
13Department of Hematology, Shanghai Changhai Hospital Affiliated to The 2nd Military Medical University, Shanghai, China
14Department of Cellular and Molecular Diabetes, The Diabetes Institute of City of Hope National Medical Center, Duarte, CA
15Department of Hematology and Hematopoietic Cell Transplantation, The Beckman Research Institute, City of Hope National Medical Center, Duarte, CA

Recipient tissue expression of programmed death-ligand 1 (PD-L1, B7H1) down-regulates graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT), but this information has not been translated clinically.  Here we demonstrate a critical role for recipient PD-L1 expression in preventing both acute and chronic GVHD while preserving graft-versus-leukemia (GVL) effects when donor CD4+ T cells are temporarily depleted in vivo early after HCT.  Depletion of donor CD4+ T cells increases serum IFN-γ concentrations and enhances recipient tissue expression of PD-L1 and donor CD8+ T cell expression of the PD-L1 receptors CD80 and PD-1. In GVHD target tissues, depletion of CD4+ T cells increases anergy and apoptosis of infiltrating CD8+ T cells in a manner that depends on recipient PD-L1 expression, thereby preventing damage to intestinal Paneth cells and stem cells, hepatocytes, and thymic medullary epithelial cells, and preventing both acute and chronic GVHD. In lymphoid tissues, depletion of CD4+ T cells augments CD8+ T cell proliferation without increasing CD8+ T cell anergy or apoptosis, resulting in expansion of donor CD8+ T cells and strong GVL effects. Therefore, temporary depletion of donor CD4+ T cells early after HCT represents a novel approach for preventing GVHD while preserving GVL effects. This work was supported by NIH R01 AI066008 and Nesvig Lymphoma Fundation (to D.Z.) and by NSFC 81090413, 81270638 (to J.W.).

Disclosures: Forman: Amgen: Consultancy ; Mustang: Research Funding . Martin: Janssen: Consultancy ; Enlivex: Consultancy ; RegImmune: Research Funding ; Neovii: Research Funding ; Pharmacyclics: Consultancy ; Pfizer: Consultancy .

*signifies non-member of ASH